Lutterworth pharma firm merges with major global player
Leicestershire-based pharmaceutical and healthcare services consultancy NeoHealthHub has completed a merger with German pharma, biotech and medtech giant PharmaLex Group.
The Lutterworth firm was founded in 2013 to provide comprehensive market access, data and capability development solutions across all phases of the pharmaceutical and healthcare brand lifecycle.
It employs 50 people across its four business units NeoNavitas, NeoN, NeoSypher and NeoOptima.
The merger with PharmaLex will help to build a pan-European practice covering markets including the UK, Germany, Italy, Spain, France and Scandinavia.
The German company was recently acquired by AmerisourceBergen for around £1.1bn.
Alantra advised NeoHealthHub on the transaction, with partner Anthony Harrington taking the lead.
NeoHealthHub CEO Simon Doyle said: “We’ve known Anthony for several years and met regularly to talk about strategy, when would be the right time to partner with another business and preparing NHH for a transaction. That guidance and preparation proved invaluable when we started the process with PharmaLex.
“The Alantra team were everything we could ask for in a trusted advisor – they understood our business model and the market dynamics, identified the key value drivers and provided the strategic guidance we needed to ensure a successful completion. We’ve achieved a great outcome with a partner who shares similar values and corporate culture and created an organisation that allows us to operate in a truly agile way, maximising opportunities as they emerge.”
Harrington said: “It was a pleasure to have advised Simon and his team on the merger of NeoHealthHub with PharmaLex. They have built a very strong business and we are delighted to have helped them find the right partner for their next growth phase.
“This transaction also demonstrates Alantra’s continued strength in medical communications M&A and in pharma commercialisation more generally – this is our ninth transaction in the last two years alone, with several others ongoing. We continue to see strong interest from both strategic and private equity investors into this sector.”
Dr. Thomas Dobmeyer, CEO of Pharmalex, added: “The merger with NHH is a welcome step for both our businesses and we are delighted to welcome the talented and knowledgeable team of market access, data and capabilities experts. By combining our expertise, we are better able to support our clients globally with their market access, data and capability needs and at the same time build a very successful local market access business that now includes the UK.”
